Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 3
1957 3
1959 2
1960 1
1961 2
1967 1
1969 1
1970 1
1971 3
1973 1
1975 1
1976 3
1978 2
1979 2
1980 1
1981 5
1983 4
1984 3
1985 3
1986 8
1987 1
1988 2
1989 6
1990 2
1991 3
1992 7
1993 4
1994 3
1995 1
1996 5
1997 5
1998 9
1999 7
2000 8
2001 9
2002 8
2003 6
2004 15
2005 8
2006 7
2007 8
2008 13
2009 13
2010 19
2011 20
2012 11
2013 17
2014 15
2015 13
2016 17
2017 23
2018 30
2019 20
2020 35
2021 31
2022 24
2023 45
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

485 results

Results by year

Filters applied: . Clear all
Page 1
Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation.
Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, Mountantonakis SE, Gibson DN, Harding JD, Ellis CR, Ellenbogen KA, DeLurgio DB, Osorio J, Achyutha AB, Schneider CW, Mugglin AS, Albrecht EM, Stein KM, Lehmann JW, Mansour M; ADVENT Investigators. Reddy VY, et al. N Engl J Med. 2023 Nov 2;389(18):1660-1671. doi: 10.1056/NEJMoa2307291. Epub 2023 Aug 27. N Engl J Med. 2023. PMID: 37634148 Clinical Trial.
Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation.
Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, Niebauer M, Makati K, Halperin B, Gauri A, Morales G, Shao M, Cerkvenik J, Kaplon RE, Nissen SE; STOP AF First Trial Investigators. Wazni OM, et al. Among authors: morales g. N Engl J Med. 2021 Jan 28;384(4):316-324. doi: 10.1056/NEJMoa2029554. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33197158 Clinical Trial.
Molecular Diversity. Editorial.
Morales GA. Morales GA. Mol Divers. 2009 Feb;13(1):3. doi: 10.1007/s11030-008-9106-8. Mol Divers. 2009. PMID: 19137407 No abstract available.
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD.
Akahoshi Y, Spyrou N, Hogan WJ, Ayuk F, DeFilipp Z, Weber D, Choe HK, Hexner EO, Rösler W, Etra AM, Sandhu K, Yanik GA, Chanswangphuwana C, Kitko CL, Reshef R, Kraus S, Wölfl M, Eder M, Bertrand H, Qayed M, Merli P, Grupp SA, Aguayo-Hiraldo P, Schechter T, Ullrich E, Baez J, Beheshti R, Gleich S, Kowalyk S, Morales G, Young R, Kwon D, Nakamura R, Levine JE, Ferrara JLM, Chen YB. Akahoshi Y, et al. Among authors: morales g. Blood Adv. 2023 Aug 22;7(16):4479-4491. doi: 10.1182/bloodadvances.2023009885. Blood Adv. 2023. PMID: 37315175 Free PMC article.
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Al Malki MM, London K, Baez J, Akahoshi Y, Hogan WJ, Etra A, Choe H, Hexner E, Langston A, Abhyankar S, Ponce DM, DeFilipp Z, Kitko CL, Adekola K, Reshef R, Ayuk F, Capellini A, Chanswangphuwana C, Eder M, Eng G, Gandhi I, Grupp S, Gleich S, Holler E, Javorniczky NR, Kasikis S, Kowalyk S, Morales G, Özbek U, Rösler W, Spyrou N, Yanik G, Young R, Chen YB, Nakamura R, Ferrara JLM, Levine JE. Al Malki MM, et al. Among authors: morales g. Blood Adv. 2023 Sep 12;7(17):5189-5198. doi: 10.1182/bloodadvances.2023009853. Blood Adv. 2023. PMID: 37235690 Free PMC article. Clinical Trial.
The utility of biomarkers in acute GVHD prognostication.
Spyrou N, Akahoshi Y, Ayuk F, Holler E, Choe H, Etra A, Hogan WJ, Rösler W, Hexner E, DeFilipp Z, Reshef R, Chanswangphuwana C, Qayed M, Kraus S, Eder M, Javorniczky NR, Grupp SA, Kitko CL, Merli P, Aguayo-Hiraldo P, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Khan A, Kowalyk S, Morales G, Young R, Nakamura R, Chen YB, Levine JE, Ferrara JLM. Spyrou N, et al. Among authors: morales g. Blood Adv. 2023 Sep 12;7(17):5152-5155. doi: 10.1182/bloodadvances.2023009929. Blood Adv. 2023. PMID: 37142257 Free PMC article. No abstract available.
Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effects.
Prado-Acosta M, Jeong S, Utrero-Rico A, Goncharov T, Webster JD, Holler E, Morales G, Dellepiane S, Levine JE, Rothenberg ME, Vucic D, Ferrara JLM. Prado-Acosta M, et al. Among authors: morales g. Sci Transl Med. 2023 Dec 20;15(727):eadf8366. doi: 10.1126/scitranslmed.adf8366. Epub 2023 Dec 20. Sci Transl Med. 2023. PMID: 38117900
The COVID-19 experience in Africa and the Middle East.
Bizri AR, Al Akoury N, Mhlanga T, Morales GDC, Haridy H, Hussey GD, Srivastava A. Bizri AR, et al. Among authors: morales gdc. Ann Med. 2023 Dec;55(1):2222641. doi: 10.1080/07853890.2023.2222641. Ann Med. 2023. PMID: 37345635 Free PMC article. Review.
Effective treatment of low-risk acute GVHD with itacitinib monotherapy.
Etra A, Capellini A, Alousi A, Al Malki MM, Choe H, DeFilipp Z, Hogan WJ, Kitko CL, Ayuk F, Baez J, Gandhi I, Kasikis S, Gleich S, Hexner E, Hoepting M, Kapoor U, Kowalyk S, Kwon D, Langston A, Mielcarek M, Morales G, Özbek U, Qayed M, Reshef R, Rösler W, Spyrou N, Young R, Chen YB, Ferrara JLM, Levine JE. Etra A, et al. Among authors: morales g. Blood. 2023 Feb 2;141(5):481-489. doi: 10.1182/blood.2022017442. Blood. 2023. PMID: 36095841 Free PMC article.
485 results